Moderate Acute MalnutritionNCT06305442
Microbiota Directed Food for Children With Moderate Acute Malnutrition
A study testing Microbiota-Directed Food and Ready-to-Use Supplementary Food in people with Moderate Acute Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.
Trial summary
Moderate acute malnutrition (MAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Read more about this study
- Who is it for?
- Ages 6 to 24 months
- Conditions the study is for
- Moderate Acute Malnutrition
- What is being tested?
- Microbiota-Directed Food and Ready-to-Use Supplementary Food
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 230 participants
- Where
- 1 siteBangladesh
- Study dates
- 15 Apr 2024to 28 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 24 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Parent(s) willing to sign consent form
- Children aged 6-24 months
- WLZ score <-2 to ≥-3 and/or MUAC ≥115 mm to <125 mm without bilateral pedal edema at the time of randomization
Who cannot join
- Medical conditions: Malnourished children with complications requiring acute phase treatment in a hospital, children with tuberculosis or any chronic illness(es).
- Any congenital/acquired disorder affecting growth, i.e., known case of trisomy-21 or cerebral palsy; children on an exclusion diet for the treatment of persistent diarrhea; having known history of soy, peanut or milk protein allergy
- Severe anaemia (< 8 gm/dl)
- Antibiotic use (within last 7 days before the onset of intervention)
- Receiving concurrent treatment for another condition
- children participating in other food intervention program
Trial locations and contacts
1 site in 1 country.
Tahmeed Ahmed, MBBS, PhD contact
Bangladesh1 site
Mirpur Study site
Dhaka
Dr. Jinat Alam, MPH, MBBS, +8801676742255, jinat.alam@icddrb.com
About this study
Official title: Efficacy of Microbiota-Directed Food in Children With Moderate Acute Malnutrition in Dhaka, Bangladesh
Moderate acute malnutrition (MAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing MAM is crucial to prevent its progression to severe acute malnutrition (SAM) and to ensure healthy child development. To meet the nutritional requirement of MAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use supplementary food. The investigator propose this efficacy trial to establish the evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with MAM in comparison to the standard RUSF.
Read the detailed description
Burden: Moderate acute malnutrition (MAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing MAM is crucial to prevent its progression to severe acute malnutrition (SAM) and to ensure healthy child development. MAM affects a significant number of children globally, particularly in low- and middle-income countries where malnutrition is prevalent. According to the 2022 Bangladesh Demographic and Health Survey (2022 BDHS), 24% of children under the age of 5 are stunted, while 11% are wasted. The prevalence of worldwide MAM children is higher than that of children with SAM and 31.3 million under 5 children (~70%) was moderately wasted among all those children who were acutely malnourished in 2022. MAM children are found to be suffering from relative gut microbial immaturity, which is related to their growth faltering. Ready-to-use supplementary food (RUSF) is a key component of the outpatient treatment of MAM in community-based management. RUSF, being a ready-to-use food, does not require preparation or refrigeration and provides the necessary nutrients and energy for recovery from MAM.
Knowledge gap: Researchers at icddr,b in collaboration with Washington University in St. Louis, have developed a Microbiota-Directed Complementary Food (MDCF) formulation (based on locally available food ingredients) that has the potential to repair the gut microbiota of children with malnutrition. Results from a recently conducted study of MDCF on Bangladeshi children suffering from MAM showed that the children who received the food exhibited significantly faster rates of ponderal growth compared to those treated with a standard ready-to-use supplementary food (PR#18073). Early evidence, however, is limited to a small sample of children with MAM.
Relevance: To meet the nutritional requirement of MAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use supplementary food by modifying the original MDCF recipe to meet the nutritional requirement of MAM children as well as to make it align with the existing WHO/UNICEF specifications for a nutritional intervention for treating acute malnutrition. The proposed formulation of MDF with adequate calorie content will improve the nutritional status by modulating and improving the gut microbial dysbiosis that is present in MAM children. Therefore, the investigator propose this efficacy trial to establish the evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with MAM in comparison to the standard RUSF.
Hypothesis (if any):
The locally developed MDF would be proven beneficial in nutritional recovery, repairing microbiota and restoring plasma biomarkers of healthy growth when compared to standard RUSF among children suffering from MAM.
Objectives:
Primary objectives:
•To assess the efficacy of MDF in improving the weight-for-length Z score (WLZ) of MAM children
Secondary:
- To investigate the efficacy of MDF in repairing the microbiota of MAM children
- To measure the efficacy of MDF in improving the Weight-for-Age Z-score (WAZ) in children with MAM
- To measure the efficacy of MDF in improving the Length-for-Age Z-score (LAZ) in children with MAM
- To explore and validate the impact of MDF supplement in restoring plasma and fecal biomarkers
- To monitor the change produced by MDF in rebalancing the body composition (fat mass % and fat-free mass %)
- To explore the efficacy of MDF in improving the cognitive, motor, and language function of MAM children
Methods:
Study Design: This study will be a double-blind, randomized controlled trial.
Participants: The trial will recruit 6-24-months-old children with Moderate Acute Malnutrition
Study Site: Bauniabadh and the adjacent slum area of Mirpur in Dhaka city.
Sample Size: 230; 2 arms; 115 per arm)
Intervention: Children in one arm will receive the MDF, and the children in the control arm will receive the conventional RUSF.
The children will receive intervention for 12 weeks with either the MDF or RUSF.
- 6-24-months children with MAM - 12 weeks intervention with MDF + 12 weeks follow up
- 6-24-months children with MAM - 12 weeks intervention with RUSF + 12 weeks follow up
Study Procedure Screening, and enrolment of study participants will be done in Bauniabadh and the adjacent slum area of Mirpur in Dhaka city. Initially 6-24-months-old children will be screened by the study health workers. Parents of eligible children who meet the inclusion criterion will be approached about enrolment into the study. A trained Field Research Assistant will explain the study in detail, answer any questions from the parent(s), and invite the parent(s) to enroll the child in the study. After acquiring consent from the parents, at the beginning of the study, information will be sought on the demographic characteristics (families' wealth, standard of housing, family structure, home environment, parental characteristics etc.). Morbidity data will be collected weekly during the intervention period, and biweekly in the follow-up phase.
In this study, nutritional status will be assessed through anthropometry, comparing with WHO growth reference standards. BIA is a method of assessing body composition by measuring body fat in relation to lean body mass. It is an integral part of a health and nutrition assessment. BIA will be used to measure total fat and fat-free mass before and after treatment. This non-invasive test simply involves the placement of electrodes on the person's hand and foot. A low-level, imperceptible electrical current is sent through the body. The flow of the current is affected by the amount of water in the body. The device measures how this signal is impeded through different types of tissue as it passes through the body and provides estimates of body water from which body fat is calculated.
A food frequency questionnaire will be used to collect data on Infant and Young Child Feeding (IYCF) practices. Food frequency data will be evaluated using the Minimum Acceptable Diet indicator as it meets standards for both minimum dietary diversity and minimum meal frequency.
The Bayley Scales of Infant and Toddler Development (BSID-IV) will be used to assess the early childhood development (cognitive, motor, and language development) before and after the intervention. The Caregiver Reported Early Development Instruments (CREDI) long form, developed by Harvard University, will also be used in this study (21).
Blood samples will be collected before, after the intervention/treatment, and at the end of the follow-up period for measuring haemoglobin, serum protein (total protein and albumin), thiamine, zinc, vitamin B12, vitamin D, and folate levels.
Non-diarrheal stool samples will be collected at enrolment, then monthly during the intervention and follow-up phase from all the participants for measuring biomarkers of gut inflammation and assessment of the composition of gut microbiota and features of the microbiome.
Oral swab samples will be collected by using commercial kit from each child at enrolment, after the intervention/treatment, and at the end of the follow-up period for measuring microbiota.
- Conditions
- Moderate Acute Malnutrition
- Being tested
- Microbiota-Directed Food, Ready-to-Use Supplementary Food
- Keywords
- Microbiota Directed Food, Gut microbiota, MAM, Bangladesh
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Microbiota-Directed FoodDietary supplement
Also called MDF
MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
Ready-to-Use Supplementary FoodDietary supplement
Also called RUSF
RUSF is standard ready-to-use supplementary food for MAM children aged 6 months and above.
| Study group | Role | What they receive |
|---|---|---|
| Microbiota Directed Food (MDF) | Experimental | Each participant will receive 12 weeks of MDF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period. Receives: Dietary Supplement: Microbiota-Directed Food |
| Ready-to-Use Supplementary Food (RUSF) | Active comparator | Each participant will receive 12 weeks of RUSF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period. Receives: Dietary Supplement: Ready-to-Use Supplementary Food |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean change in Weight-for-Length Z-score (WLZ)
In this study, nutritional status will be assessed through anthropometric measurement before enrolment, then biweekly till completion of intervention and monthly during 12 weeks follow up.
Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
Secondary outcomes (6)
Microbial community repair
Non-diarrheal stool samples will be collected at enrolment, then monthly during the intervention and follow-up phase from all the participants for assessment of the composition of gut microbiota and features of the microbiome.
Oral swab samples will be collected by using commercial kit from each child at enrolment, after the intervention/treatment, and at the end of the follow-up period for measuring microbiota.
Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
Validated plasma and faecal biomarkers of health status (prioritized Luminex/ELISA panel including mediators of growth, systemic inflammation, gut inflammation/entero-pathogen burden)
Blood samples will be collected before, after the intervention/treatment, and at the end of the follow-up period.
Non-diarrheal stool samples will be collected at enrolment, then monthly during the intervention and follow-up phase from all the participants for measuring biomarkers of gut inflammation.
Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
Mean change in Weight-for-Age Z-score (WAZ)
In this study, nutritional status will be assessed through anthropometric measurement before enrolment, then biweekly till completion of intervention and monthly during 12 weeks follow up.
Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
Mean change in Length-for-Age Z-score (LAZ)
In this study, nutritional status will be assessed through anthropometric measurement before enrolment, then biweekly till completion of intervention and monthly during 12 weeks follow up.
Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
Mean change in body composition (% body fat mass and % fat-free mass)
In this study, nutritional status will be also assessed through Bioelectrical impedance at enrolment and after completion of intervention
Measured: Baseline to 12 weeks of intervention
Bayley Scales of early childhood development (cognitive, motor, language development)
The Bayley Scales of Infant and Toddler Development (BSID-IV) will be used to assess the early childhood development (cognitive, motor, and language development) before and after the intervention. The Bayley-4 utilizes standard scores to assess a child's developmental progress compared to their age peers. Derived from individual raw scores, standard scores (with a mean of 100 and standard deviation of 15) offer a standardized metric for comparisons across Bayley-4 domains. The interpretation of standard scores on the Bayley-4 involves comparing an individual child's scores to the normative data provided in the test manual. Scores falling within one standard deviation (85-115) are considered within the average range, while scores below 85 in any domain may indicate potential developmental delays or concerns in that respective domain. Conversely, scores above 115 may suggest advanced development in that respective domain. Higher scores will mean better development.
Measured: Baseline to 12 weeks of intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2024
- Study start15 Apr 2024 (estimated)
- Primary completion31 Oct 2025 (estimated)
- Study completion28 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Moderate Acute MalnutritionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double blind, randomized, parallel group, clinical trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 230 participants (estimated)
Sponsor and investigators
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
- Sponsor type
- University, hospital or other
- Collaborators
- Washington University School of Medicine
- Responsible party
- Sponsor
- Investigators
- Ishita Mostafa, BDS, MPH, Principal investigator, International Centre for Diarrhoeal Disease Research, Bangladesh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06305442
- Sponsor's protocol ID
- PR-24031
- Status last verified
- Feb 2024
- First submitted
- 5 Mar 2024
- Last updated
- 24 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Microbiota-Directed Food in Children With Moderate Acute Malnutrition in Dhaka, Bangladesh
- ClinicalTrials.gov ID
- NCT06305442
- Acronym / sponsor ID
- PR-24031
- Conditions
- Moderate Acute Malnutrition
- Keywords
- Microbiota Directed Food, Gut microbiota, MAM, Bangladesh
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 230 participants (estimated)
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, BangladeshUniversity, hospital or other
- Collaborators
- Washington University School of Medicine
- Study start
- 15 Apr 2024 (estimated)
- Primary completion
- 31 Oct 2025 (estimated)
- Study completion
- 28 Feb 2026 (estimated)
- First posted
- 12 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Moderate acute malnutrition (MAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing MAM is crucial to prevent its progression to severe acute malnutrition (SAM) and to ensure healthy child development. To meet the nutritional requirement of MAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use supplementary food. The investigator propose this efficacy trial to establish the evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with MAM in comparison to the standard RUSF.
Detailed description
Burden: Moderate acute malnutrition (MAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing MAM is crucial to prevent its progression to severe acute malnutrition (SAM) and to ensure healthy child development. MAM affects a significant number of children globally, particularly in low- and middle-income countries where malnutrition is prevalent. According to the 2022 Bangladesh Demographic and Health Survey (2022 BDHS), 24% of children under the age of 5 are stunted, while 11% are wasted. The prevalence of worldwide MAM children is higher than that of children with SAM and 31.3 million under 5 children (~70%) was moderately wasted among all those children who were acutely malnourished in 2022. MAM children are found to be suffering from relative gut microbial immaturity, which is related to their growth faltering. Ready-to-use supplementary food (RUSF) is a key component of the outpatient treatment of MAM in community-based management. RUSF, being a ready-to-use food, does not require preparation or refrigeration and provides the necessary nutrients and energy for recovery from MAM.
Knowledge gap: Researchers at icddr,b in collaboration with Washington University in St. Louis, have developed a Microbiota-Directed Complementary Food (MDCF) formulation (based on locally available food ingredients) that has the potential to repair the gut microbiota of children with malnutrition. Results from a recently conducted study of MDCF on Bangladeshi children suffering from MAM showed that the children who received the food exhibited significantly faster rates of ponderal growth compared to those treated with a standard ready-to-use supplementary food (PR#18073). Early evidence, however, is limited to a small sample of children with MAM.
Relevance: To meet the nutritional requirement of MAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use supplementary food by modifying the original MDCF recipe to meet the nutritional requirement of MAM children as well as to make it align with the existing WHO/UNICEF specifications for a nutritional intervention for treating acute malnutrition. The proposed formulation of MDF with adequate calorie content will improve the nutritional status by modulating and improving the gut microbial dysbiosis that is present in MAM children. Therefore, the investigator propose this efficacy trial to establish the evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with MAM in comparison to the standard RUSF.
Hypothesis (if any):
The locally developed MDF would be proven beneficial in nutritional recovery, repairing microbiota and restoring plasma biomarkers of healthy growth when compared to standard RUSF among children suffering from MAM.
Objectives:
Primary objectives:
•To assess the efficacy of MDF in improving the weight-for-length Z score (WLZ) of MAM children
Secondary:
- To investigate the efficacy of MDF in repairing the microbiota of MAM children
- To measure the efficacy of MDF in improving the Weight-for-Age Z-score (WAZ) in children with MAM
- To measure the efficacy of MDF in improving the Length-for-Age Z-score (LAZ) in children with MAM
- To explore and validate the impact of MDF supplement in restoring plasma and fecal biomarkers
- To monitor the change produced by MDF in rebalancing the body composition (fat mass % and fat-free mass %)
- To explore the efficacy of MDF in improving the cognitive, motor, and language function of MAM children
Methods:
Study Design: This study will be a double-blind, randomized controlled trial.
Participants: The trial will recruit 6-24-months-old children with Moderate Acute Malnutrition
Study Site: Bauniabadh and the adjacent slum area of Mirpur in Dhaka city.
Sample Size: 230; 2 arms; 115 per arm)
Intervention: Children in one arm will receive the MDF, and the children in the control arm will receive the conventional RUSF.
The children will receive intervention for 12 weeks with either the MDF or RUSF.
- 6-24-months children with MAM - 12 weeks intervention with MDF + 12 weeks follow up
- 6-24-months children with MAM - 12 weeks intervention with RUSF + 12 weeks follow up
Study Procedure Screening, and enrolment of study participants will be done in Bauniabadh and the adjacent slum area of Mirpur in Dhaka city. Initially 6-24-months-old children will be screened by the study health workers. Parents of eligible children who meet the inclusion criterion will be approached about enrolment into the study. A trained Field Research Assistant will explain the study in detail, answer any questions from the parent(s), and invite the parent(s) to enroll the child in the study. After acquiring consent from the parents, at the beginning of the study, information will be sought on the demographic characteristics (families' wealth, standard of housing, family structure, home environment, parental characteristics etc.). Morbidity data will be collected weekly during the intervention period, and biweekly in the follow-up phase.
In this study, nutritional status will be assessed through anthropometry, comparing with WHO growth reference standards. BIA is a method of assessing body composition by measuring body fat in relation to lean body mass. It is an integral part of a health and nutrition assessment. BIA will be used to measure total fat and fat-free mass before and after treatment. This non-invasive test simply involves the placement of electrodes on the person's hand and foot. A low-level, imperceptible electrical current is sent through the body. The flow of the current is affected by the amount of water in the body. The device measures how this signal is impeded through different types of tissue as it passes through the body and provides estimates of body water from which body fat is calculated.
A food frequency questionnaire will be used to collect data on Infant and Young Child Feeding (IYCF) practices. Food frequency data will be evaluated using the Minimum Acceptable Diet indicator as it meets standards for both minimum dietary diversity and minimum meal frequency.
The Bayley Scales of Infant and Toddler Development (BSID-IV) will be used to assess the early childhood development (cognitive, motor, and language development) before and after the intervention. The Caregiver Reported Early Development Instruments (CREDI) long form, developed by Harvard University, will also be used in this study (21).
Blood samples will be collected before, after the intervention/treatment, and at the end of the follow-up period for measuring haemoglobin, serum protein (total protein and albumin), thiamine, zinc, vitamin B12, vitamin D, and folate levels.
Non-diarrheal stool samples will be collected at enrolment, then monthly during the intervention and follow-up phase from all the participants for measuring biomarkers of gut inflammation and assessment of the composition of gut microbiota and features of the microbiome.
Oral swab samples will be collected by using commercial kit from each child at enrolment, after the intervention/treatment, and at the end of the follow-up period for measuring microbiota.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double blind, randomized, parallel group, clinical trial
| Arm | Type | Receives |
|---|---|---|
| Microbiota Directed Food (MDF) | Experimental | Dietary Supplement: Microbiota-Directed FoodEach participant will receive 12 weeks of MDF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period. |
| Ready-to-Use Supplementary Food (RUSF) | Active comparator | Dietary Supplement: Ready-to-Use Supplementary FoodEach participant will receive 12 weeks of RUSF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period. |
Who may qualify
- Ages
- 6 to 24 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Parent(s) willing to sign consent form
- Children aged 6-24 months
- WLZ score <-2 to ≥-3 and/or MUAC ≥115 mm to <125 mm without bilateral pedal edema at the time of randomization
Key exclusion criteria (6 listed)
- Medical conditions: Malnourished children with complications requiring acute phase treatment in a hospital, children with tuberculosis or any chronic illness(es).
- Any congenital/acquired disorder affecting growth, i.e., known case of trisomy-21 or cerebral palsy; children on an exclusion diet for the treatment of persistent diarrhea; having known history of soy, peanut or milk protein allergy
- Severe anaemia (< 8 gm/dl)
- Antibiotic use (within last 7 days before the onset of intervention)
- Receiving concurrent treatment for another condition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Microbiota-Directed FoodAlso: MDFMDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal. | Dietary supplement | Microbiota Directed Food (MDF) |
| Ready-to-Use Supplementary FoodAlso: RUSFRUSF is standard ready-to-use supplementary food for MAM children aged 6 months and above. | Dietary supplement | Ready-to-Use Supplementary Food (RUSF) |
Primary outcome
Mean change in Weight-for-Length Z-score (WLZ)
Time frame: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
In this study, nutritional status will be assessed through anthropometric measurement before enrolment, then biweekly till completion of intervention and monthly during 12 weeks follow up.
6 secondary outcomes
Microbial community repair
Time frame: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
Validated plasma and faecal biomarkers of health status (prioritized Luminex/ELISA panel including mediators of growth, systemic inflammation, gut inflammation/entero-pathogen burden)
Time frame: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
Mean change in Weight-for-Age Z-score (WAZ)
Time frame: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
Mean change in Length-for-Age Z-score (LAZ)
Time frame: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up
Mean change in body composition (% body fat mass and % fat-free mass)
Time frame: Baseline to 12 weeks of intervention
Bayley Scales of early childhood development (cognitive, motor, language development)
Time frame: Baseline to 12 weeks of intervention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2024.
- Individual participant dataSharing planned: No
Related trials for Moderate Acute Malnutrition
Enrolling by invitation
Effectiveness of Positive Deviance/Hearth in Treating Uncomplicated Moderate Acute Malnutrition in Children 6-59 Months in Mymensingh Division, Bangladesh
Moderate Acute Malnutrition (MAM), Undernutrition
Active, not recruiting
Regular Growth Monitoring (RGM) of Young Children in Guinea-Bissau
Severe Acute Malnutrition, Moderate Acute Malnutrition (MAM)
Not yet recruiting
Reduced Dosage and/or Visitation Protocol for the Treatment of Acute Malnutrition in Kenya
Acute Malnutrition in Childhood, Acute Malnutrition, Severe
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tahmeed Ahmed, MBBS, PhD contact
Ishita Mostafa, BDS, MPH principal investigator
International Centre for Diarrhoeal Disease Research, Bangladesh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Microbiota-Directed Food and Ready-to-Use Supplementary Food in people with Moderate Acute Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Ishita Mostafa, BDS, MPH (01755512359, ishita.mostafa@icddrb.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean change in Weight-for-Length Z-score (WLZ) (time frame: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2024.